Shanghai Shen Lian Biomedical Corp (SHG:688098) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Shen Lian Biomedical Corp (688098)
Shanghai Shen Lian Biomedical Corp (SHG:688098) has a market capitalization of $510.77 Million (CN¥3.49 Billion) as of June 22, 2026. Listed on the SHG stock exchange, this China-based company holds position #12267 globally and #3587 in its home market, demonstrating a 5.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Shen Lian Biomedical Corp's stock price CN¥8.50 by its total outstanding shares 410644000 (410.64 Million). Review 688098 total liabilities to assess the company's total debt and financial obligations.
Shanghai Shen Lian Biomedical Corp Market Cap History: 2019 to 2026
Shanghai Shen Lian Biomedical Corp's market capitalization history from 2019 to 2026. Data shows change from $974.91 Million to $510.77 Million (-19.40% CAGR).
Shanghai Shen Lian Biomedical Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Shen Lian Biomedical Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.85x
Shanghai Shen Lian Biomedical Corp's market cap is 1.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $974.91 Million | $253.81 Million | $77.96 Million | 3.84x | 12.51x |
| 2020 | $938.84 Million | $337.73 Million | $129.51 Million | 2.78x | 7.25x |
| 2021 | $649.13 Million | $358.43 Million | $110.20 Million | 1.81x | 5.89x |
| 2022 | $471.95 Million | $328.59 Million | $61.10 Million | 1.44x | 7.72x |
| 2023 | $449.47 Million | $301.49 Million | $31.52 Million | 1.49x | 14.26x |
| 2024 | $328.69 Million | $303.41 Million | -$44.74 Million | 1.08x | N/A |
| 2025 | $533.60 Million | $288.27 Million | -$19.09 Million | 1.85x | N/A |
Competitor Companies of 688098 by Market Capitalization
Companies near Shanghai Shen Lian Biomedical Corp in the global market cap rankings as of June 22, 2026.
Key companies related to Shanghai Shen Lian Biomedical Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Shanghai Shen Lian Biomedical Corp Historical Marketcap From 2019 to 2026
Between 2019 and today, Shanghai Shen Lian Biomedical Corp's market cap moved from $974.91 Million to $ 510.77 Million, with a yearly change of -19.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥510.77 Million | -4.28% |
| 2025 | CN¥533.60 Million | +62.34% |
| 2024 | CN¥328.69 Million | -26.87% |
| 2023 | CN¥449.47 Million | -4.76% |
| 2022 | CN¥471.95 Million | -27.30% |
| 2021 | CN¥649.13 Million | -30.86% |
| 2020 | CN¥938.84 Million | -3.70% |
| 2019 | CN¥974.91 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Shanghai Shen Lian Biomedical Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $510.77 Million USD |
| MoneyControl | $510.77 Million USD |
| MarketWatch | $510.77 Million USD |
| marketcap.company | $510.77 Million USD |
| Reuters | $510.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Shen Lian Biomedical Corp
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.